China to India: Diagnostic Import Trade Route

The China to India Diagnostic corridor is one of India's established pharmaceutical import routes from China, with 4,373 shipments documented worth a combined $1.1B USD. The route is dominated by ASSURE TECH (HANGZHOU)CO.,LTD , which alone accounts for roughly 61% of all import value, reflecting the consolidated nature of China's diagnostic export sector.

Across 132 active China suppliers, the average shipment value stands at $250.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 82% of all shipments, consistent with diagnostic's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 19.7%, placing it at rank #14 among India's top diagnostic import origins globally.

On the Indian buyer side, key Indian importers include MOKSHY SURGICALS , MATRIX LABS , MATRIX LABS and 85 others. MOKSHY SURGICALS is the single largest Indian importer with 55 shipments valued at $672.5M USD.

India's diagnostic imports from China are driven primarily by a handful of large-scale China manufacturers. ASSURE TECH (HANGZHOU)CO.,LTD with 37 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 132 active exporters signals a competitive but concentrated market — Indian buyers benefit from China supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — ASSURE TECH (HANGZHOU)CO.,LTD , GUANGZHOU WONDFO BIOTECH CO LTD , GUANGZHOU WONDFO BIOTECH CO LIMITED — together account for 92% of total trade value on this route. The average shipment value of $250.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as tsh quantitative test (flourescence immunoassay diagnostic kit)(list 3 sl no 84) and hba1c quantitative test(flourescence immunoassay diagnostickit)(list 3 sl no 84) , suggesting that Indian buyers tend to consolidate orders across related product lines from the same China supplier.

On the buying side, MOKSHY SURGICALS is the largest importer with 55 shipments worth $672.5M USD — representing 61% of all diagnostic imports from China on this route. A total of 88 buyers are active on this corridor.